etanercept,tofacitinib,rituximab,natalizumab,vedolizumab,ustekinumab,tocilizumab,abatacept,golimumab,secukinumab,infliximab,adalimumab,ocrelizumab,certolizumab,apremilast
abbvie,novartis,roche,bms,janssen,takeda,biogen,amgen,ucb pharmaceuticals,pfizer
['vedolizumab', 'dance', 'golimumab', 'certolizumab', 'derm', 'tofacitinib', 'natalizumab', 'etanercept', 'adalimumab', 'psoriasis', 'crohn', 'toci', 'tocilizumab', 'tofa', 'secukinumab', 'infliximab', 'selection,(-selectionlte),(-selection lte),(-selection-lte)', ' ust ', 'ritux', 'inflammatory,bowel', ' vedo', 'ustekinumab', 'lupus', 'abatacept', 'ulcerative colitis', 'ibd', 'apremilast', 'ocrelizumab', ' uc ']
 for the shoutout to our srma on combining biologics/small molecules, now open access full text for those interested #aibd2022 
Assoc Professor, Director Clinical/Translational Research @WUGastro @IbdWustl, AE @IBDJournals, Deputy Director, SPARC-IBD, via @OfficialJipmer @MayoClinicGIHep